Related Experiment Video

Updated: Aug 22, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK

Eun Hye Lee1, Jae-Wook Chung2, Eunji Sung3

  • 1Joint Institute of Regenerative Medicine, Kyungpook National University, Daegu 41566, Korea.

International Journal of Molecular Sciences
|November 11, 2022
PubMed

Insights

Pyruvate dehydrogenase kinase 4 (PDK4) promotes bladder cancer growth and metastasis. Silencing PDK4 reduced cancer cell migration, invasion, and tumor growth in preclinical models, identifying PDK4 as a potential biomarker.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Bladder cancer presents a significant global health challenge due to high rates of metastasis and mortality.
  • Identifying novel biomarkers for bladder cancer diagnosis and treatment is crucial.

Purpose of the Study:

  • To investigate the role of Pyruvate dehydrogenase kinase 4 (PDK4) in bladder cancer progression.
  • To identify PDK4-related protein alterations in bladder cancer.

Main Methods:

  • Comparative proteomic analysis was performed on bladder cancer cell lines with PDK4 knockdown.
  • In vivo studies utilized a PDK4 knockdown xenograft model in nude mice.

Main Results:

  • Elevated PDK4 expression was observed in high-grade bladder cancers.
  • PDK4 silencing significantly reduced bladder cancer cell migration and invasion.
  • Reduced tumor growth was observed in the PDK4 knockdown xenograft model.

Conclusions:

  • PDK4 plays a critical role in bladder cancer metastasis and growth.
  • PDK4 influences bladder cancer progression through alterations in ERK, SRC, and JNK signaling pathways.
  • PDK4 represents a potential therapeutic target and diagnostic biomarker for bladder cancer.
Keywords:
bladder cancerinvasionmetastasismuscle-invasive bladder cancer (MIBC)pyruvate dehydrogenase kinase 4 (PDK4)

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K